8 results
Search Results
2. A Nordic-Baltic perspective on indications for proton therapy with strategies for identification of proper patients.
- Author
-
Brandal, Petter, Bergfeldt, Kjell, Aggerholm-Pedersen, Ninna, Bäckström, Gloria, Kerna, Irina, Gubanski, Michael, Björnlinger, Kirsten, Evensen, Morten E., Kuddu, Maire, Pettersson, Erik, Brydøy, Marianne, Hellebust, Taran P., Dale, Einar, Valdman, Alexander, Weber, Lars, and Høyer, Morten
- Subjects
INTERNATIONAL agencies ,INTERPROFESSIONAL relations ,MEETINGS ,TUMORS ,ADULT education workshops ,TREATMENT effectiveness ,PATIENT selection ,PROTON therapy - Abstract
The beneficial effects of protons are primarily based on reduction of low to intermediate radiation dose bath to normal tissue surrounding the radiotherapy target volume. Despite promise for reduced long-term toxicity, the percentage of cancer patients treated with proton therapy remains low. This is probably caused by technical improvements in planning and delivery of photon therapy, and by high cost, low availability and lack of high-level evidence on proton therapy. A number of proton treatment facilities are under construction or have recently opened; there are now two operational Scandinavian proton centres and two more are under construction, thereby eliminating the availability hurdle. Even with the advantageous physical properties of protons, there is still substantial ambiguity and no established criteria related to which patients should receive proton therapy. This topic was discussed in a session at the Nordic Collaborative Workshop on Particle Therapy, held in Uppsala 14–15 November 2019. This paper resumes the Nordic-Baltic perspective on proton therapy indications and discusses strategies to identify patients for proton therapy. As for indications, neoplastic entities, target volume localisation, size, internal motion, age, second cancer predisposition, dose escalation and treatment plan comparison based on the as low as reasonably achievable (ALARA) principle or normal tissue complication probability (NTCP) models were discussed. Importantly, the patient selection process should be integrated into the radiotherapy community and emphasis on collaboration across medical specialties, involvement of key decision makers and knowledge dissemination in general are important factors. An active Nordic-Baltic proton therapy organisation would also serve this purpose. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
3. Ongoing and future clinical trials in particle therapy in the Nordic countries.
- Author
-
Witt Nyström, Petra, Bratland, Åse, Minn, Heikki, and Grau, Cai
- Subjects
CLINICAL trials ,INTERPROFESSIONAL relations ,RADIOTHERAPY ,EVIDENCE-based medicine - Abstract
In the Nordic countries, as in the rest of the world, particle therapy as a radiotherapy modality, is evolving, albeit the hard evidence for the clinical benefit still is scarce. However, a common goal for the Nordic countries is to include a minimum of 80% of the patients treated with particle therapy into clinical trials. In this paper, we summarize the current status of clinical trials involving particle therapy in the Nordic countries, with an overview of both active and coming trials. So far, one is closed for inclusion and data are being analyzed, seven trials are actively recruiting patients and several more trials are underway. No common Nordic trial has yet been designed, nor is in the planning phase, and the authors will discuss the obstacles as well as the opportunities a common Nordic platform may represent. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
4. Novel technologies in radiotherapy in the Nordic countries - report from the NACP2020/21 conference.
- Author
-
Korreman, Stine Sofia, Vogelius, Ivan Richter, Abdi, Ahmed Jibril, Hansen, Søren Baarsgaard, and Behrens, Claus Preibisch
- Subjects
PHYSICS ,SERIAL publications ,MEDICAL technology ,ARTIFICIAL intelligence ,CONFERENCES & conventions ,PROTON therapy ,RADIOTHERAPY ,MOTION capture (Human mechanics) - Abstract
The article discusses technologies in radiotherapy in the Nordic countries. Topics discussed include focus on development and implementation of new technologies; role of online format to attract a higher active attendance than prior meetings; and use of MR accelerators for treatment of moving tumors.
- Published
- 2021
- Full Text
- View/download PDF
5. Adjuvant radiotherapy in retroperitoneal sarcomas. A Scandinavian Sarcoma Group study of 97 patients.
- Author
-
Trovik, Linn H., Ovrebo, Kjell, Almquist, Martin, Haugland, Hans Kristian, Rissler, Pehr, Eide, Johan, Engellau, Jacob, Monge, Odd R., Nyhus, Anniken B., Elde, Ingvild K., and Jebsen, Nina L.
- Subjects
CANCER relapse ,ACADEMIC medical centers ,CHI-squared test ,CONFIDENCE intervals ,MEDICAL cooperation ,RADIOTHERAPY ,RESEARCH ,RESEARCH funding ,SURVIVAL analysis (Biometry) ,RETROPERITONEUM ,DATA analysis software ,DESCRIPTIVE statistics ,MANN Whitney U Test ,PROGNOSIS ,CANCER ,CANCER risk factors - Abstract
Background. Currently there is no consensus on the use of adjuvant radiotherapy (RT) in retroperitoneal sarcoma (RPS). We have analysed clinical outcomes in patients with localised RPS treated at two Scandinavian Sarcoma Group (SSG) centres: Haukeland University Hospital (HUH), Bergen, Norway and Skåne University Hospital (SUH), Lund, Sweden to clarify the effects of adjuvant RT on local control and overall survival (OS). Material and methods. Local databases and registers at HUH and SUH as well as the SSG central register were used to identify RPS patients. Patients with localised RPS who underwent surgery in Bergen between 1988 and 2009 and in Lund from 1998 to 2009 were included. Medical records were examined for clinical data, tumour characteristics, treatment factors and follow-up status. Archived tumour sections and tumour tissue were reviewed, and when necessary, restained and reclassified. Cox regression was used to analyse the association of potential prognostic factors with local recurrence-free survival (LRFS), metastasis-free survival (MFS) and OS. Results. The study included 97 patients: 52 from Norway and 45 from Sweden. The proportion of high-grade tumours was 73%. The five-year LRFS, MFS and OS were 55%, 59% and 60%, respectively. RT was significantly associated with improved local control resulting in a five-year LRFS of 77% compared with 39% without (p < 0.001). Furthermore, five-year OS was 71% in the RT group in contrast to 52% with surgery alone (p = 0.019). In the adjusted analysis RT proved to be a significant factor also for MFS (HR = 0.42, 95% CI 0.20-0.88, p = 0.021). In addition, high-grade malignancy, large tumour and positive surgical margin were risk factors for local recurrence. High malignancy grade was the only significant adverse prognostic factor for metastasis. High age and high-grade malignancy were negative prognostic factors for OS. Conclusion. Adjuvant RT was significantly associated with an improved five-year LRFS and OS. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
6. Late radiation effects to the rectum and anus after treatment for prostate cancer; validity of the LENT/SOMA score.
- Author
-
Lund, Jo-, Kaasa, Stein, Wibe, Arne, Widmark, Anders, and Fransson, Per
- Subjects
ANUS ,CONFIDENCE intervals ,PROSTATE tumors ,RADIOTHERAPY ,RECTUM ,RESEARCH evaluation ,SCALES (Weighing instruments) ,STATISTICS ,DATA analysis ,RANDOMIZED controlled trials ,INTER-observer reliability ,RESEARCH methodology evaluation ,DATA analysis software ,DESCRIPTIVE statistics - Abstract
Background. The Late Effects Normal Tissue/Subjective Objective Management Analytic (LENT/SOMA) system for grading of side effects after radiotherapy was proposed several years ago. Only a few studies have previously been performed on the validity of the LENT/SOMA. The aim of the present study was to validate the LENT/SOMA scoring system for recto-anal side effects after treatment for prostate cancer in a randomized trial. Material and methods. A total of 875 patients with locally advanced prostate cancer were randomized to either hormonal treatment alone or hormonal treatment plus radiotherapy in the Scandinavian Prostate Cancer Group 7 (SPCG-7) study. At least three years after treatment was started, the 178 patients that were randomized at St. Olavs Hospital were approached. One hundred and three patients of these accepted inclusion. The side effects according to LENT/SOMA were graded by oncologist and nurse. In addition, side effects were graded according to the European Organisation for Research and Treatment of Cancer and the Radiation Therapy Oncology Group (EORTC/RTOG) toxicity scale and patient-reported health-related quality of life (HRQOL) questionnaires. Content/face validity, sensitivity and inter-rater reliability of the LENT/SOMA tables for rectum were analyzed. Results. Content/face analysis of LENT/SOMA revealed serious problems. Significant correlations (Spearman's rho > 0.4) were found between three of 15 LENT/SOMA items and similar HRQOL items. LENT/SOMA score made it possible to detect significant differences between the two groups of patients (p < 0.001), EORTC/RTOG toxicity score did not (p = 0.138). Inter-rater reliability was acceptable. Conclusions. LENT/SOMA scoring system for recto-anal side effects after radiotherapy for prostate cancer displays serious difficulties in the present study. Replacement of LENT/SOMA tables for rectum by a combination of patient-reported HRQOL questionnaires, clinical examination and objective physiological measurements might be called for. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
7. Abstracts of Theses from the Nordic Countries.
- Author
-
Lof, Johan, Danielsson, Rimma, Johansson, Amanda, Gisselsson, David, Skog, Anna-Lena Hjelm, Hongyun Li, Dasu, Alexandru, and Bergenmar, Mia
- Subjects
CANCER treatment ,RADIOTHERAPY ,NUCLEAR medicine ,HYPOXEMIA - Abstract
Presents several abstracts on cancer treatment in the Nordic countries. Development of a general framework for optimization of radiation therapy; Role of nuclear medicine in diagnosis of breast cancer and regional lymph nodes; Impact of hypoxia on novel radiotherapy.
- Published
- 2001
- Full Text
- View/download PDF
8. Radiotherapy in Scandinavia.
- Author
-
Olsen, Dag R. and Bruland, Øyvind S.
- Subjects
RADIOTHERAPY ,CANCER - Abstract
Examines the role modern radiotherapy in the management of cancer in Scandinavia. Improvement of local tumor control by increasing doses of radiation; Significance of hypoxic modification and overall trial; Implications to radiation oncology and medical practice.
- Published
- 1998
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.